Peter S. Greenleaf - 02 Jan 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role: Chief Executive Officer, Director
Signature: /s/ Peter S. Greenleaf
Issuer symbol: AUPH
Transactions as of: 02 Jan 2026
Net transactions value: -$1,805,046
Form type: 4
Filing time: 05 Jan 2026, 16:10:03 UTC
Previous filing: 07 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Greenleaf Peter	Chief Executive Officer, Director	#140, 14315-118 AVENUE, EDMONTON, ALBERTA, CANADA	/s/ Peter S. Greenleaf	05 Jan 2026	0001363683

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AUPH	Common Stock	Award	$0	+165,384	+9.2%	$0.000000	1,954,329	02 Jan 2026	Direct	F1
transaction	AUPH	Common Stock	Tax liability	$1,805,046	-113,169	-5.8%	$15.95	1,845,037	02 Jan 2026	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026.
F2	Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards.
F3	Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,257 common shares were acquired on May 30, 2025 and 1,620 common shares were acquired on November 28, 2025.